Without effective quality management, it’s impossible to take full … [Read More...]
White Papers
Speeding up MDR Technical Documentation approval
Prior to marketing a medical device, manufacturers must comply with … [Read More...]
Sponsored Content
Human-centered design drives meaningful product development
Delve helps pharmaceutical and medical device companies develop human-centered design cultures. By Ami Verhalen, Vice President of Design, Delve When your innovation and new product design (NPD) … [Read More...]
Want DFM that delivers value?
Your First Step Is the Most Important Design for Manufacturability (DFM) involves designing parts or products so that they meet the critical needs of an application while simultaneously being … [Read More...]
Human Factors Engineering: 3 Practical Tips for User-Centered Design
by Orlando Soto (Engineering Manager), Omar Bermudez (Senior Industrial Designer), and Sarah Faulkner (Director of Marketing) Human factors engineering is a critical - and in some industries, … [Read More...]
Modernizing Clinical Research: Keeping Pace with Medical Device & Diagnostics Innovation
By: Kevin Liang, Senior Director Strategy, Veeva Medical Device & Diagnostics Clinical studies are the foundation of successful development of device and diagnostic products. Studies are also … [Read More...]
Let BD Peripheral Vascular OEM’s Experts Share Their Knowledge and Experience to Help You Develop or Expand Your Device Product Portfolio
For over a century, C. R. Bard, Inc. – now part of BD – has been a leader in the medical device industry. BD Peripheral Intervention OEM products combine BD’s technologies with a proven commitment to … [Read More...]
Mergers & Acquisitions.
Illumina to acquire Grail for $8B, expands cancer early detection
Illumina (NSDQ:ILMN) announced today that it entered into an agreement to acquire Grail for cash and stock consideration of $8 billion. Last week, it was reported that Illumina was looking to purchase the cancer detection startup that spun out from the company four years ago and the companies confirmed that to be true today. Grail was […]
Boston Scientific may buy Afib treatment startup Farapulse
Boston Scientific (NYSE:BSX) announced today that it signed an investment agreement with an option to acquire Farapulse. Menlo Park, Calif.-based Farapulse develops a pulsed-field ablation (PFA) system for treating atrial fibrillation (Afib) and other cardiac arrhythmias. The PFA system is designed with a sheath, a generator and catheters to ablate heart tissue through creating a therapeutic […]
MedTech 100 roundup: Stagnant week for industry
Medtech stocks made a run at a new peak over the past week, but ultimately remained mostly unchanged from the previous seven days. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week at 89.3 (Sep. 18), marking a 0.3% gain from the 89.03 points registered at […]
Illumina may buy back Grail
Illumina (NSDQ:ILMN) may acquire Grail for more than $8 billion — four years after it spun out the cancer detection startup. That’s according to a Bloomberg report out yesterday, which cited people familiar with the matter. Analysts told Bloomberg that the acquisition would put Illumina — a giant in the DNA sequencing space — in direct […]
Livongo, Teladoc divulge more details of proposed $18.5M merger
Teladoc (NYSE:TDOC) and Livongo Health (NSDQ:LVGO) today filed a joint proxy statement in connection with a proposed merger. Last month, the companies entered into a definitive merger agreement worth approximately $18.5 million. At the time, each share of Livongo was set to be exchanged for 0.5920 shares of Teladoc, plus cash consideration of $11.33 per Livongo share, […]
Intersect ENT to acquire Fiagon for $71.1M
Intersect ENT (NSDQ:XENT) announced today that it entered into an agreement to acquire Fiagon AG Medical Technologies for $71.1 million. The $71.1 million (€60 million) cash deal will see Intersect ENT make an initial $17.8 million (€15 million) payment at the time of closing and further $17.8 (€15 million) annual payments over the following three years. […]
Bruker acquires Canopy Biosciences
Bruker Corp. (NSDQ:BRKR) announced today that it acquired biomarker imaging technology developer Canopy Biosciences. Billerica, Mass.-based Bruker said in a news release that the acquisition, for which financial details were not disclosed, enhances its offering in targeted multi-omics and fluorescence-based imaging technologies and combines its global reach with Canopy’s success to date. Canopy develops high multiplex […]
